Biomarker bioanalysis

The bioanalysis of endogenous biomarkers requires a broad range of expertise. Biomarker molecules vary extensively with respect to concentrations that need to be quantified, the biomarker class, its chemical characteristics, as well as the levels already present in the sample matrix. Another challenge could be that reference material is not available for that analyte.

In the case of biomarker analysis, the context-of-use of the analytical data is key in developing a method that is fit for the purpose.

Lablytica can analyze both large and small molecules using either enzyme-linked immunosorbent assay (ELISA), UPLC-MS/MS, or a combination of both methods (hybrid assays). We balance high throughput and high accuracy with our semi-automated processes, providing data which is both accurate and precise in a timely manner.

Lablytica supports Elypta in the development of their metabolism-based liquid biopsy platform.